FDA |
U.S. Food and Drug Administration |
CDER |
The Center for Drug Evaluation and Research |
CBER |
The Center for Biologics Evaluation and Research |
WHO |
World health organization |
mAb |
Monoclonal antibody |
bsAb |
Bispecific antibody |
ADC |
Antibody drug conjugate |
CAR T |
Chimeric antigen receptor T cell |
TNF |
Tumor necrosis factor |
GPCR |
G-protein coupled receptor |
GLP-1 |
Glucagon-like peptide-1 |
GIP |
Glucose-dependent insulinotropic polypeptide |
AAV |
Adeno-associated virus |
GM-CSF |
Granulocyte-macrophage colony stimulating factor |
ON |
Oligonucleotide |
ASO |
Antisense oligonucleotide |
siRNA |
Short interfering RNA |
GalNac |
N-acetylgalactosamine |
CRISPR |
Clustered regularly interspaced short palindromic repeats |
T1D |
Type 1 diabetes mellitus |
T2D |
Type 2 diabetes mellitus |
HbA1c |
Hemoglobin A1c |
HSC |
Hematopoietic stem cell |
MSC |
Mesenchymal stem cell |
NF-κB |
Nuclear factor -κB |
JAK |
Janus kinase |
STAT |
Transducer and activator of transcription |
SYK |
Spleen tyrosine kinase |
TYK2 |
Tyrosine kinase 2 |
BTK |
Bruton’s tyrosine kinase |
AtD |
Atopic dermatitis |
Th |
T helper |
PDE4 |
Phosphodiesterase 4 |
EASI |
Eczema area and severity index |
H4R |
Histamine H4 receptor |
MAdCAM |
Mucosal addressin cell adhesion molecule |
S1P |
Sphingosine 1-phosphate |
CNS |
Central nervous system |
OA |
Osteoarthritis |
NSAID |
Nonsteroidal anti-inflammatory drug |
COX |
Cyclooxygenase |
NGF |
Nerve growth factor |
MMP |
Matrix metalloproteinase |
CGRP |
Calcitonin gene-related peptide |
ND |
Neurodegenerative disease |
AD |
Alzheimer’s disease |
PD |
Parkinson’s disease |
AChEIs |
Acetylcholinesterase inhibitors |
NMDA |
N-methyl-D-aspartic acid |
DMTs |
Disease-modifying treatments |